291 results about "Fucose" patented technology

The invention discloses a normal-temperature bacteria liquid enteric-coated targeted colonization microcapsule and a preparation method thereof. The invention belongs to the technical field of biological medicine. The structure of the room-temperature bacterial liquid protection microcapsule is as follows: an inner layer is an activity maintaining layer and mainly consists of a sodium alginate-calcium chloride polyelectrolyte compound (the thickness is 50-100 microns); the middle layer is a pH response release layer and is mainly composed of hydroxypropyl methyl cellulose phthalate (HPMCP, dissolved at pH of 6.8 or above) and nano calcium carbonate particles (the particle size is 50nm, and the proportion is 10% w / w); the outer layer is a mucous membrane adhesion layer, and the main components of the mucous membrane adhesion layer comprise fucose modified chitosan (Fuc-CS, targeted colonic mucous membrane lectin protein) and carbomer 940 (pH sensitive adhesion polymer); the method is a microcapsule capable of preserving the bacterial liquid at normal temperature and accurately targeting colon release and adhesion colonization and a process thereof, the problem of flora activity loss caused by a freeze-drying process can be solved, in addition, the process does not need freeze-drying equipment, and the production cost is reduced.

The invention belongs to the field of food, and particularly relates to application of a nutritional composition for assisting in improving memory ability. The invention provides application of a nutritional composition in preparation of food for assisting in improving memory ability of offspring. The nutritional composition comprises the following necessary components: active folic acid substances and fucosyllactose, moreover, in the nutritional composition, the mass ratio of the active folic acid substance to the fucosyllactose is (0.0001-0.0015): (0.5-10), the food is ingested by a mother to play the role of assisting in improving the memory ability of the offspring, the mother is in a gestation period and / or a lactation period, and the maternal is in the gestation period and / or the lactation period. The filial generation comprises a fetal-stage filial generation and / or an infant-stage filial generation and an optional child-stage filial generation. A large number of studies find that when active folic acid substances and fucosyllactose which are combined according to a certain proportion are supplemented to a mother at the beginning of the gestation period, the memory ability of offspring can be remarkably improved in an auxiliary mode.

The use of a nutritional composition in the preparation of a food product for assisting in improving the memory ability in offspring, wherein the nutritional composition contains the following essential components: an active folic acid substance and fucosyllactose; and in the nutritional composition, the mass ratio of the active folic acid substance to the fucosyllactose is (0.0001-0.0015):(0.5-10). The food product exerts the effect of assisting in improving the memory ability in offspring, wherein the food product is ingested by a mother, the mother is preganant and / or lactating, and the offspring comprises fetal offspring and / or infant offspring and optionally childhood offspring.

The invention belongs to the field of functional substance research, and particularly relates to a nutritional composition for promoting absorption of fatty acid and mineral substances and application. The nutritional composition provided by the invention comprises necessary active ingredients shown as the following (I) and (II): (I) 1, 3-dioleic acid-2-palmitic acid triglyceride; (II) a milk fat globule membrane, and / or, 2 '-fucosyllactose; moreover, in the nutritional composition, the mass ratio of the necessary active component shown in (I) to the necessary active component shown in (II) is (5-10): (0.5-10). The combination of OPO and MFGM and / or 2 '-FL provided by the invention can be beneficial to promoting the absorption of the body to fatty acids and mineral substances, and especially can be beneficial to promoting the transmembrane transport capability of intestinal cells of the body to fatty acids and mineral substances, so that the absorption efficiency is improved.

The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or nutritional compositions comprising the combination. The combination or compositions are for use in treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child. The mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL). The present invention also relates to the use of a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child, wherein the mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL).

The present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual wherein the composition comprises Bifidobacterium longum subsp. Infantis and a mixture of HMO consisting of 2 '-fucosyllactose (2FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6'-sialyllactose (6SL), 3 '-sialyllactose (3SL), and 3-fucosyllactose (3FL). The present invention also provides compositions for use in preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing respiratory disorders in an individual, and / or preventing and / or reducing the risk of developing asthma in an individual.

The present invention relates to a composition comprising a Bifidobacterium longum transitional microorganism and a mixture of human milk oligosaccharides (HMOs) consisting of 2'-fucosyllactose (2'-FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), and 3'-sialyllactose (3SL), and optionally lacto-N-fucopentaose I (LNFP-I), 3- fucosyllactose (3-FL) and / or lacto-N-neotetraose (LNnT), wherein the Bifidobacterium longum transitional microorganism has an Average Nucleotide Identity (ANI) of at least 98% with CNCM I-5942. The invention also relates to the use of the composition for preventing, reducing the risk of and / or treating an infection in a subject. The invention also provides the composition for use in promoting a long-term immune benefit in a subject, preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.

The present disclosure relates to a composition for balancing the immune system of a neonatal or infant subject, the composition comprising an effective amount of 2 '-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6 '-sialyllactose, and lactose-N-tetrasaccharide.

The invention relates to a gene modified cell for producing HMOs, which can be applied to synthesis of difucosyllactose, and belongs to the technical field of gene engineering. The invention provides a genetically modified cell, which contains an alpha-1, 2-fucosyltransferase polypeptide and a heterologous nucleic acid sequence of the alpha-1, 3-fucosyltransferase polypeptide. The genetically modified cell has higher activity of synthesizing difucosyllactose, and does not contain synthetic 3-fucosyllactose or lower side activity of synthetic 2 '-fucosyllactose. The technical scheme of the invention has positive significance for industrial production of human milk oligosaccharide, and the method is green, efficient and sustainable, is beneficial to industrial large-scale production, and has important practical value.

The application discloses a composition for improving asthenopia and application, and the composition is compounded by longissimum bifidobacterium longum subsp i772, 2'-fucose lactose, lacto-N-neotetraose and lutein with a weight ratio of 1-100:460-1600:120-400:0.03-0.35. The composition for improving asthenopia has a synergistic effect in the function of relieving asthenopia, longissimum bifidobacterium longum subsp i772, 2'-fucose lactose, lacto-N-neotetraose and lutein can effectively relieve the apoptosis of eye cells caused by asthenopia, and the composition can be applied to infant formula milk powder, children's formula milk powder, fermented milk and health food.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

Provided herein are host cells capable of producing a human milk oligosaccharide (HMO), such as yeast cells that include one or more heterologous nucleic acids encoding one or more enzymes of the HMO biosynthetic pathway, such as a fucosyltransferase, GDP-mannose dehydratase, lactose permease, and / or fucose synthase. Also provided are fermentation compositions including the disclosed host cells, as well as related methods of producing and recovering HMOs generated by the host cells.

The invention provides a series of GDP-mannose dehydratase polypeptides which can be applied to synthesis of GDP-fucose, and belongs to the technical field of enzyme engineering. The GDP-mannose dehydratase polypeptide comprises a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to that of a polypeptide shown in SEQ ID NO: 1, or a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to that of a polypeptide M1-13. The GDP-mannose dehydratase polypeptide disclosed by the invention has relatively high catalytic activity.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

The present application relates to a series of GDP-fucose synthetase polypeptides, which can be applied to the synthesis of human milk oligosaccharides (HMOs) precursor GDP-fucose, belonging to the field of enzyme engineering technology. In certain embodiments, the polypeptide having catalytic GDP-4-keto-6-deoxymannose converted into GDP-fucose comprises an amino acid sequence which is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identical to SEQ ID NO: 1 and / or to the polypeptide M1-14. The present application provides a series of polypeptides for synthesizing GDP-fucose.

The application discloses a kind of based on fermentation of Sanghuangjun preparation's Radix Tetrastigae polysaccharide and its use.The Radix Tetrastigae polysaccharide is composed of polysaccharide with weight percentage content more than 99%;The polysaccharide is composed of galactose, mannose, fucose and 3-O-methyl-galactose, and the molar ratio is 8.5-11.0:1.5-3:0.8-1.5:1.0.The Radix Tetrastigae polysaccharide is extracted, separated and purified from Sanghuang fermentation Radix Tetrastigae.The Radix Tetrastigae polysaccharide has significant antitumor activity and regulates intestinal flora structure efficacy, can be directly used as antitumor and / or regulate intestinal flora structure function product, and also can be used for preparing antitumor and / or regulating intestinal flora structure function product.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium bifidum NKUFB3-12 and a composition thereof in preparation of products for relieving allergic diseases and / or regulating intestinal flora caused by allergy. The preservation number of the bifidobacterium bifidum NKUFB3-12 is GDMCC (China General Microbiological Culture Collection Center) No. 64013. The bifidobacterium bifidum NKUFB3-12 disclosed by the invention has excellent functional characteristics of relieving allergic diseases and regulating allergic intestinal flora, and also has excellent probiotic characteristics of acid resistance, cholate resistance and oxidation resistance, and the strain is safe and has no adverse side effect after being taken. The invention provides a composition. The composition comprises bifidobacterium bifidum NKUFB3-12 and 2 '-fucosyllactose (2'-FL), and the NKUFB3-12 is compounded with the 2 '-FL to show an effective inhibition effect on the imbalance of allergic immune response.

The present disclosure relates to a composition comprising Lactobacillus crispatus, Lactobacillus rhamnosus, Lactobacillus jensenii, Lactobacillus gasseri and 2'-fucosyllactose for use as a supplement to support healthy vaginal microbiota in pregnant women.

The present invention relates to nutritional compositions comprising digestible carbohydrates, lipids, proteins, 3-fucosyl lactose (3-FL) and a butyrate source, which are suitable for providing nutrition to an infant or young child suffering from or at risk of developing a food allergy, preferably cow milk protein or egg allergy, wherein the protein is or consists essentially of hydrolysed protein and / or free amino acids, and wherein the butyrate is provided in the form of dietary butyrate and / or by non-digestible saccharides selected from non-digestible polysaccharides, non-digestible oligosaccharides or mixtures thereof capable of undergoing microbial fermentation in the gastrointestinal tract to produce butyrate, and uses thereof.

The invention discloses a composition for preventing and / or treating alcoholic liver diseases, a product and application thereof. The present invention relates to a composition comprising: breast milk oligosaccharides and vitamins; the breast milk oligosaccharide comprises fucosyllactose and sialic acid lactose; the composition can provide nutritional support for patients with alcoholic liver diseases, repair intestinal mucosal barrier, reduce endotoxin entering blood, improve abundance of beneficial bacteria in intestinal tracts and reduce inflammatory response, so as to achieve the purpose of preventing and / or treating alcoholic liver diseases induced by alcohol.

To provide technique that improves a taste added by polyphenols.SOLUTION: A composition for improving the taste of a polyphenol-containing composition comprises fucose as an active ingredient. There is also provided a method for improving the taste of a polyphenol-containing composition, by blending fucose with the polyphenol-containing composition. The polyphenol-containing composition preferably contains at least one polyphenol selected from the group consisting of cacao polyphenol, theaflavin, isoflavone, chlorogenic acid, catechin, curcumin, anthocyanin, shogaol, and gingerol.SELECTED DRAWING: None

The invention discloses a lutein composition for relieving asthenopia and a preparation method of the lutein composition, and belongs to the field of functional foods. Phycocyanin and kelp polyphenol are mixed and react to obtain modified phycocyanin; fucoidin and beta-glucuronidase are mixed and react to obtain modified fucose; mixing the fish collagen peptide and zinc chloride to react to obtain a collagen peptide-zinc chelate; the xanthophyll siliceous cage compound and the modified phycocyanin are mixed and react to obtain a first compound; mixing and reacting the first compound and modified fucose to obtain a second compound; mixing and reacting the second compound, collagen peptide-zinc chelate and krill oil to obtain a lutein compound; mixing and reacting the second compound, collagen peptide-zinc chelate and krill oil, adding trehalose, and mixing and reacting to obtain a xanthophyll compound; and mixing the xanthophyll compound and maltodextrin to obtain the xanthophyll composition.

The present application relates to a kind of 2'-fucosyllactose producing recombinant escherichia coli and its construction method and application, belong to the field of bioengineering technology.The present application expresses 2'-fucosyllactose remediation synthesis pathway related gene in recombinant escherichia coli, including the gene fkp of coding GDP-fucose pyrophosphorylase FKP and the gene futC of coding fucosyltransferase FutC, respectively in the upstream of fkp gene and futC gene expression macromolecular coagulation material protein FUSLCD after the modification of coagulation tag GCN4, and replaces replicon, constructs a strain of high-yield 2'-fucosyllactose recombinant escherichia coli, yield and production intensity reach 38.68g / L and 0.35g / L / h respectively.It has good application prospect, has the potential of industrial application.

The invention relates to the technical field of pet oral health care, in particular to a compound seaweed source composition for assisting in improving oral health of dogs and cats and application of the compound seaweed source composition. The invention discloses a compound seaweed source composition for assisting in improving oral health of dogs and cats. The compound seaweed source composition comprises sodium alginate and fucoidan, the value of mannuronic acid (M) / guluronic acid (G) in the sodium alginate is 0.96-1.18; the fucoidan is prepared from mannose, glucuronic acid, galactose, xylose and fucose; the weight ratio of the sodium alginate to the fucoidan is 9: 2. The compound seaweed source composition disclosed by the invention has the effects of inhibiting the proliferation of pathogenic bacteria in the oral cavity of a pet, slowing down the rising rate of health indexes of the oral cavity of the pet, inhibiting the generation of volatile organic compounds and ammonia gas in the oral cavity, improving saliva components, slowing down the generation of dental plaque and the like, and can effectively improve the health condition of the oral cavity of the pet.

Disclosed is a composition (204) comprising galactose and fucose in monosaccharide form for use as a promotor of tissue re-epithelialization, wherein the tissue is non-ophthalmic tissue.

The present invention relates to a monoclonal antibody reacting with a glycopeptide and use thereof. The present invention provides a monoclonal antibody which is an epitope of both a fucose moiety and an amino acid of a peptide moiety. The antibody of the present invention is a monoclonal antibody reacting with a glycopeptide containing a core fucose and an amino acid of 4 or more residues continuously from an asparagine of an additional sugar chain toward a C-terminal side, the antibody being an epitope of both the core fucose of the glycopeptide and an amino acid of the glycopeptide which is 3 or more residues from the asparagine of the additional sugar chain toward the C-terminal side.

The invention provides yellow-rose yellow-meat boletus fucomannan as well as a composition, a preparation method and application thereof, and belongs to the technical field of biological medicine mass health. The fucomannan has a structure represented by a general formula in an attached drawing of the abstract, and n represents the number of sugar repeating units and is a natural number. The weight-average molecular weight of the fucose glucomannan galactan of the boletus fucose is 10 kDa to 20 kDa, the polydispersity coefficient of the fucose glucomannan galactan is 1 to 2, and the molar ratio of glucose to mannose to fucose to galactose is 1.00 to 3.08 to 2.84 to 14.86. The boletus fucomannan and the composition containing the boletus fucomannan and the composition containing the boletus fucomannan and the composition containing the boletus fucomannan have the effects of promoting proliferation of beneficial bacteria, reducing the pH value of a microenvironment, increasing secretion of SCFAs and lactic acid, adjusting composition of intestinal microorganisms and the like, and have the function of improving the intestinal microecology. Therefore, the invention also discloses the fucomannan-glucomannan of the boletus roseus and the fucomannan-glucomannan of the boletus roseus and the fucomannan-glucomannan of the boletus roseus and the fucomannan-glucomannan of the boletus roseus and the fucomannan of the composition of the boletus roseus and the fucomannan of the composition of the boletus roseus and the fucomannan of the composition of the boletus roseus and the fucomannan of the composition of the composition of the composition of the composition of the composition of the composition of the composition of

This invention relates to the field of lyophilized formulation technology, specifically disclosing an esupagglutide α-nano-lyophilized micelle and its preparation method. The micelles of this invention utilize polylactic-co-hydroxyacetic acid copolymer and sodium phosphatidylglycerol as micelle carriers, with arginine and cysteine ​​providing branching synergistic effects. Homogenization via film formation and low-temperature lyophilization yield lyophilized nano-micelle powder. The nano-micelle powder reduces protein oxidative decomposition during lyophilization, decreases impurity fragments, and reduces various non-fucose glycosylation, basic components (succinimide, methionine oxidation products), N-terminal deletion, Asn deamidation, and Met and Trp residue oxidation impurities that affect product quality. Product quality analysis and animal experiments after reconstitution show good resistance to impurities and degradation risk. The reconstituted esupagglutide α-nano-micelle system exhibits better stability and sustained-release properties, enhancing the hypoglycemic sustained-release effect 72 hours after injection, significantly improving upon conventional non-micelle formulations.

The application belongs to the technical field of natural products, and discloses purified fermentation dendrobium polysaccharide and application thereof in skin barrier repair. The application provides a fermentation dendrobium polysaccharide DOP-1A, which comprises mannose, arabinose, gluconic acid, glucose, galactose and fucose; and a fermentation dendrobium polysaccharide DOP-2A, which comprises mannose and glucose. The fermentation dendrobium polysaccharide with high purity and uniform structure is obtained by using a fermentation dendrobium powder extraction solution, alcohol precipitation and column chromatography purification. Research proves that the fermentation dendrobium polysaccharide obtained by separation and purification has the effects of skin moisturizing and skin barrier repair, and also has anti-inflammatory activity. The extraction and separation method provided by the application can efficiently extract and purify polysaccharide from fermentation dendrobium, is suitable for the fields of skin barrier repair and anti-inflammatory, and has good application prospect and value.

The invention discloses plasmid-free engineered Escherichia coli for synthesizing lactoyl-N-fucosyl pentasaccharide I as well as a construction method and application of the plasmid-free engineered Escherichia coli, and belongs to the field of genetic engineering. Starting from a genome integration strain for efficiently synthesizing lactoyl-N-tetraose, alpha-1, 2-fucosyltransferase TeSA is introduced, the integration copy number of the alpha-1, 2-fucosyltransferase TeSA is optimized, a plasmid-free strain for efficiently synthesizing the LNFPI is constructed through multi-step reinforcement of a GDP-fucose synthesis route and metabolic flux optimization, finally, the extracellular titer of the LNFPI is 3.98 g / L, and the extracellular titer of the LNFPI is 3.98 g / L; and the method has a good industrialization prospect.